| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CP724714 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.008 |
| mRNA | selumetinib:GDC-0941 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.008 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.008 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.13 | 0.008 |
| mRNA | temsirolimus | FIMM | pan-cancer | AAC | 0.4 | 0.009 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.15 | 0.009 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.098 | 0.01 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.089 | 0.01 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.097 | 0.01 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.01 |